None listed
Conditions
Interventions
None listed
Sponsors
Asan Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Untreated CHB Patient Cohort 1) Adult male or female patients over 20 years of age. 2) Having serum hepatitis B surface antigens for >6 months 3) Never having any evidence of liver cirrhosis, radiologically, clinically, or both. 4) Serum ALT levels at baseline 6 months. 3) Never having any evidence of liver cirrhosis, radiologically, clinically, or both. 4) Having started HBV treatment with entecavir or tenofovir.
Exclusion criteria
Exclusion criteria: 1. Untreated CHB Patient Cohort 1) Patients with evidence of HCV infection, HDV infection or HIV infection. 2) Patients with prior antiviral treatment, malignancy, or immunosuppressive agents. 3) Insufficient medical records. 4) Patients with ALT levels at baseline >1× ULN and HBV DNA 2× ULN during the initial 1 year of follow-up. 7) Patients who were followed up less than a year. 2.Treated CHB Patient Cohort 1) Patients with evidence of HCV infection, HDV infection, or HIV infection. 2) Patients with prior antiviral treatment, malignancy, or immunosuppressive agents. 3) Insufficient medical records. 4) Patients who have received a liver transplantation or have history or evidence of HCC. 5) Patients who were followed up less than a year.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HCC occurrence rate by baseline HBV DNA levels | — |
Secondary
| Measure | Time frame |
|---|---|
| HCC occurrence rate by baseline HBV DNA levels in untreated non-cirrhotic CHB patients;HCC occurrence rate by baseline HBV DNA levels in treated non-cirrhotic CHB patients | — |
Countries
Korea, Republic of
Contacts
Public ContactGi-Ae Kim
KyungHee University Medical Center
Outcome results
None listed